Data-driven insights to accelerate allogeneic cell therapy development and manage risk.
Bioinformatics Consulting for Cell and Gene Therapy
Data-driven insights to accelerate allogeneic cell therapy development and manage risk.
A bioinformatics team uniquely qualified to support cell therapy needs
Our HLA and KIR work span decades. Our researchers and scientists advance the field of immunogenetics and hematopoietic stem cell transplant/cellular therapy genomics through the CIBMTR Bioinformatics Research Program.
That experience—along with more than 35 years of patient outcomes data for hematopoietic cell transplantation and cellular therapies—allows us to develop methods that support proper donor/patient histocompatibility for allogeneic cellular therapies.
Additionally, our team can provide access to unique and expansive clinical outcomes, CIBMTR data and donor registry databases available only through our organization. Partners receive insightful data analytics and modeling based on decades of cell therapy research.
Bioinformatics insights
Identify and compare optimal cell sources (adult donors or cord blood units) with HLA/KIR characteristics that capture product criteria.
Optimize candidate donor choices to maximize target patient population coverage and minimize cost and redundant effort.
Identify favorable factors of histocompatibility and HLA/KIR genotype interpretation for therapy success.
Resolve ambiguities and missing HLA locus information in study data using population haplotype frequencies and unique expertise in HLA/KIR genotype.
Population haplotype frequency estimates for multiple U.S. and world populations developed using HLA data from millions of volunteer donors.
Project match likelihoods in certain populations, cell sources and/or geographical areas using customized modeling.
Projections derived from NMDP Registry℠ data—the most diverse repository of HLA data collected from healthy adult volunteer donors and umbilical cord blood.
Optimize cell source type, high potential genotypes and sample size to maximize target patient population coverage.
Support critical data collection
Collect, manage, and analyze critical cell and gene therapy outcomes data with industry-leading infrastructure and expertise.